Amarin

Yahoo Finance • 9 months ago

15 Best Shareholder Activism Law Firms

In this article, we discuss the 15 Best Shareholder Activism Law Firms. If you would like to discuss our detailed discussion and analysis of the shareholder activism space as of 2024, you can skip it and go directly to 5 Best Shareholder A... Full story

Yahoo Finance • 11 months ago

Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Amarin Corporation plc DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its participation in the 42nd Annual JP Morgan Healthcare Conference. Amarin’s president... Full story

Yahoo Finance • last year

New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

-- Analysis Also Found IPE Was Associated with a 41% Reduction in Total Events Compared with Placebo -- -- Subgroup Almost Exclusively Comprised of Patients with Established Cardiovascular Disease -- -- Findings Continue to Reinforce the... Full story

Yahoo Finance • last year

Amarin Corporation plc (NASDAQ:AMRN) Q3 2023 Earnings Call Transcript

Amarin Corporation plc (NASDAQ:AMRN) Q3 2023 Earnings Call Transcript November 1, 2023 Amarin Corporation plc misses on earnings expectations. Reported EPS is $-0.05 EPS, expectations were $-0.02. Operator: Welcome to Amarin Corporation'... Full story

Yahoo Finance • last year

Amarin Reports Third Quarter 2023 Financial Results

-- Company Reported Total Net Revenues of $66 Million in the Third Quarter 2023 -- -- Delivered Positive Cash Flow of $8 Million in the Quarter, Marking Fifth Consecutive Quarter of Cash Positive Operations1; Quarter-Ending Cash Position... Full story

Yahoo Finance • last year

Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded research from the landmark REDUCE-IT cardiovascular outcomes trial on the effects o... Full story

Yahoo Finance • last year

 Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior manageme... Full story

Yahoo Finance • last year

Amarin to Present at the 2023 Cantor Global Healthcare Conference

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer, is scheduled to participate via fireside c... Full story

Yahoo Finance • last year

Amarin (NASDAQ:AMRN) shareholders have endured a 83% loss from investing in the stock three years ago

It's not possible to invest over long periods without making some bad investments. But really bad investments should be rare. So spare a thought for the long term shareholders of Amarin Corporation plc (NASDAQ:AMRN); the share price is dow... Full story

Yahoo Finance • last year

12 Best NASDAQ Penny Stocks to Buy

In this article, we discuss 12 best NASDAQ penny stocks to buy. You can skip our detailed analysis of the stock market and returns of NASDAQ, and go directly to read 5 Best NASDAQ Penny Stocks to Buy. Since the start of 2023, the stock ma... Full story

Yahoo Finance • last year

Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)

-- VASCEPA® Approved in KSA To Reduce the Risk of Cardiovascular (CV) Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT-... Full story

Yahoo Finance • 2 years ago

Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression — --Data Further Advances Understanding of VASCEPA/VAZKEPA Potential Mechanism of Action-- DUBLIN, Ireland and... Full story

Yahoo Finance • 2 years ago

Amarin Reports First Quarter 2023 Financial Results and Provides Business Update

-- Stable Revenue and Cash Position Due to Performance of U.S. Business and Savings from Operational Initiatives -- -- Early Progress in Launch of VAZKEPA® (icosapent ethyl) in England & Wales; Pricing & Reimbursement Discussions in Key E... Full story

Yahoo Finance • 2 years ago

Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023

DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it will host a conference call with Aaron Berg, Interim President & CEO, and members of Amarin’s senior... Full story

Yahoo Finance • 2 years ago

Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors

DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President an... Full story

Yahoo Finance • 2 years ago

Here's Why We're Not Too Worried About Amarin's (NASDAQ:AMRN) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recur... Full story

Yahoo Finance • 2 years ago

Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today

U.S. stock markets are under heavy pressure today after two reports on job openings and factory orders came in weaker than expected. The key issue at play is a growing concern that the Federal Reserve's rate hiking campaign may spark a dee... Full story

Yahoo Finance • 2 years ago

Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health

-- Approval of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT –- -- Heart Disease Second L... Full story

Yahoo Finance • 2 years ago

Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)

New Amarin Board Believes the Company Will Thrive with Proper Stewardship New Amarin Directors are Working with Urgency to Address Issues at Amarin DUBLIN, Ireland and BRIDGEWATER, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Amarin Corpor... Full story

Yahoo Finance • 2 years ago

Amarin Announces Board Departures

DUBLIN, Ireland and BRIDGEWATER. N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that, in the interest of the Company to avoid further proxy contests, all seven i... Full story